Conquering CML The Breakthrough Paradigm Change of Treatment-free Remission - 5
Conquering CML | The Breakthrough Paradigm Change of Treatment-free Remission
ENESTfreedom Trial Drives Clinical Adoption
of Treatment-free Remission as Therapeutic
Goal in Chronic Myelogenous Leukemia
T
he international team of researchers
that conducted the ENESTfreedom
clinical trial concluded that frontline
therapy with the second-generation tyrosine kinase inhibitor (TKI) nilotinib could be
safely stopped in patients with chronic-phase
(CP) chronic myeloid leukemia (CML) who
had achieved a deep molecular response
≤ 0.0032% IS.1 Discontinuation of TKI therapy
led to treatment-free remission (TFR) in more
than half of patients. The safety of attempting
discontinuation of treatment was validated by
the fact that nearly all patients who experiTKI treatment for CML-CP is no longer necessarily a lifelong therapy. Testing will determine if the patient is in the
enced relapse were able to once again achieve 49% who achieve TFR.
their previous level of molecular response
when TKI therapy was re-started. Furthermore, no
TFR in ENESTfreedom was defined as a sustained major
patients in the ENESTfreedom study died of CML or
molecular response (http://www.clinicalomics.com
Conquering CML The Breakthrough Paradigm Change of Treatment-free Remission
Table of Contents for the Digital Edition of Conquering CML The Breakthrough Paradigm Change of Treatment-free Remission